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Background: Hypoxic tumors are refractory to radiation and chemotherapy. High expression of biomarkers related
to hypoxia in head and neck cancer is associated with a poorer prognosis. The present study aimed to evaluate the
clinicopathological significance of erythropoietin receptor (EPOR) expression in oral squamous cell carcinoma
(OSCC).
Methods: The study included 256 patients who underwent primary surgical resection between October 1996 and
August 2005 for treatment of OSCC without previous radiotherapy and/or chemotherapy. Clinicopathological
information including gender, age, T classification, N classification, and TNM stage was obtained from clinical
records and pathology reports. The mRNA and protein expression levels of EPOR in OSCC specimens were
evaluated by Q-RT-PCR, Western blotting and immunohistochemistry assays.
Results: We found that EPOR were overexpressed in OSCC tissues. The study included 17 women and 239 men
with an average age of 50.9 years (range, 26–87 years). The mean follow-up period was 67 months (range,
2–171 months). High EPOR expression was significantly correlated with advanced T classification (p< 0.001),
advanced TNM stage (p< 0.001), and positive N classification (p= 0.001). Furthermore, the univariate analysis
revealed that patients with high tumor EPOR expression had a lower 5-year overall survival rate (p= 0.0011) and
5-year disease-specific survival rate (p= 0.0017) than patients who had low tumor levels of EPOR. However, the
multivariate analysis using Cox’s regression model revealed that only the T and N classifications were independent
prognostic factors for the 5-year overall survival and 5-year disease-specific survival rates.
Conclusions: High EPOR expression in OSCC is associated with an aggressive tumor behavior and poorer prognosis
in the univariate analysis among patients with OSCC. Thus, EPOR expression may serve as a treatment target for
OSCC in the future.Background
Oral squamous cell carcinoma (OSCC), the sixth most
common cancer worldwide, is the most frequently
observed head and neck cancer in Southeast Asia [1],
but despite improvements in treatment strategy, clinical
outcomes are not satisfactory. The cancer recurs in a
large proportion of patients, and the outcome of salvage
therapies depends on the clinical stage of the disease* Correspondence: cychien3965@adm.cgmh.org.tw
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reproduction in any medium, provided the orwhen it recurs [2]. In Taiwan, many people in the lower
socioeconomic bracket chew betel nut, which causes a
significant threat to public health. In 2009, the rate of
oral cancer was approximately 14.6 per 100,000 persons
in Taiwan, and it is the fourth most common cancer in
men (http://www.doh.gov.tw/statistic). In 2007, 22,560
new cases of oral cancer were reported in the United
States, with approximately 5,370 deaths attributed to this
disease [3].
In humans, erythropoietin receptors (EPORs) can be
detected on the surface of erythroid progenitor cells in
bone marrow [4,5] and in some non-hematopoietic cells
such as vascular endothelial cells [6], retinal photorecep-
tors [7], liver stromal cells [8], neurons [9], and macro-
phages [10]. Also, recent studies have revealed that. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Lin et al. BMC Cancer 2012, 12:194 Page 2 of 7
http://www.biomedcentral.com/1471-2407/12/194EPORs play an important role in biological activities
such as physiological angiogenesis in wound healing and
the female reproductive system, and provides protection
against anoxic damage in the brain [11] and cardiovascu-
lar system [12,13].
Previous studies have reported that anemia is a poor
prognostic factor for survival in patients with cancer
[14] and that erythropoietin (EPO) treatment can im-
prove the survival rate and quality of life of patients with
anemia receiving chemoradiotherapy [15]. However,
more recent studies have shown that EPO treatment
may have different results in breast cancer and head and
neck cancer [16]. Lai et al. [17] found that the level of
EPO and EPOR can affect growth and metastasis of head
and neck cancer. A biomarker that could predict the
prognosis of oral cavity cancer would be a valuable
addition to traditional imaging. The aim of the present
study was to evaluate the clinicopathological significance
of EPOR expression in patients with OSCC.
Methods
Patients and tissue samples
The study included 256 patients who underwent primary
surgical resection between October 1996 and August
2005 for treatment of OSCC without previous radiother-
apy and/or chemotherapy. Clinicopathological informa-
tion including gender, age, tumor (T) classification, node
(N) classification, and tumor, node, metastases (TNM)
stage was obtained from clinical records and pathology
reports. The TNM status was classified according to the
2002 American Joint Committee on Cancer Staging Sys-
tem. The treatment of oral cancer will be evitable to
encounter the problems of local, regional or even distant
failure. According to the guideline of our institute, the
surgical salvage is the first choice if the tumor is oper-
able. Otherwise, the patients will undergo salvage
chemotherapy or chemoradiation if the tumor becomes
unresectable although the prognosis of this group is dis-
mal. To measure the expression of the EPOR in OSCC
tissue and adjacent non-tumor tissues, fresh tissues were
obtained from patients with OSCC biopsy specimens.
These materials were histologically confirmed by frozen
sections before quantitative RT-PCR, western blotting
and IHC assays. The present study was approved by the
Medical Ethics and the Human Clinical Trial Committee
at Chang Gung Memorial Hospital, Taiwan.
RNA extraction and quantitative RT-PCR (Q-RT-PCR)
Tissue samples were frozen in liquid nitrogen and stored
at −80 °C prior to RNA extraction. The tissue was
homogenized using a Mixer Mill Homogenizer (Qiagen,
Crawley, West Sussex, UK). Total RNA was prepared
from the frozen tissue samples using an RNeasy Mini Kit
(Qiagen) according to the manufacturer’s instructions.The RNA (2 μg) was then reverse-transcribed into cDNA
using SuperScript II Reverse Transcriptase (Invitrogen,
Carlsbad, CA, USA). For Q-RT-PCR, EPOR Taq-Man
probes (ABI) were used. Data were represented as
mean± s.d. To analyze the distribution of adjacent-non-
tumor and tumor areas, we used the Wilcoxon signed
rank test between two groups for statistical analysis.
A P-value of less than 0.05 was considered statistically
significant. GAPDH was used as an internal control for
comparison and normalization of the data. Assays were
performed in triplicate using an Applied Biosystems
Model 7500-Fast instrument.
Western blot analysis
Tissue protein extraction was carried out in frozen sam-
ples that were homogenized in radioimmunoprecipita-
tion assay (RIPA) lysis buffer [50 mM Tris–HCl (pH
7.5), 150 mM NaCl, 1% NP-40, 0.5% Na-deoxycholate,
and 0.1% sodium dodecyl sulfate (SDS)]. The protein
concentration in each sample was estimated using a
Bio-Rad Protein Assay (Bio-Rad, Hercules, CA, USA).
Immunoblotting was performed according to standard
procedures. The antibodies included polyclonal anti-
bodies against EPOR and β-actin (monoclonal; Santa Cruz
Biotechnology, Santa Cruz, CA, USA). The first antibodies
were detected by incubation with secondary antibodies
conjugated to HRP (Bio/Can Scientific, Mississauga, ON,
Canada) and developed using Western Lighting chemilu-
minescence reagent (PerkinElmer Life Sciences Inc.,
Boston, MA, USA). X-ray films were used to detect
the proteins.
Immunohistochemistry
Adjacent noncancerous and OSCC tissue samples were
selected by a pathologist based on diagnosis and micro-
scopic morphology. The tissues were fixed in 10% buf-
fered formalin, then embedded in paraffin and
decalcified in 10% EDTA solution. Representative blocks
of the formalin-fixed, paraffin-embedded tissues were
cut into 4-mm sections and deparaffinized with xylene
and rehydrated in a series of ethanol washes (100, 90,
80, and 70%). Slides were washed with phosphate-buf-
fered saline (PBS) and treated with 3% H2O2 for 30 min
to block endogenous peroxidase activity. Next, the sec-
tions were microwaved in 10 mM citrate buffer (pH 6.0)
to unmask the epitopes. After antigen retrieval, the sec-
tions were incubated with diluted anti-EPOR antibody
(sc-101444; monoclonal; 1:200; Santa Cruz Biotechnol-
ogy) for 1 h followed by washing with PBS. Horseradish
peroxidase/Fab polymer conjugate (PicTure-Plus kit;
Zymed, South San Francisco, CA, USA) was then
applied to the sections for 30 min followed by washing
with PBS. Finally, the sections were incubated in diami-
nobenzidine for 5 min to develop the signals. A negative
Figure 1 Immunostaining for EPOR expression in oral
squamous cell carcinoma. (A) The representative tumor shows
only weak EPOR immunoreactivity in the neoplastic epithelial cells at
the border of the tumor. (B) The representative tumor exhibits
diffuse and strong EPOR immunoreactivity in the neoplastic
epithelial cells. Note that some inflammatory cells are also positive
for EPOR. Original magnification, 100 × .
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ultaneously. Positive immunostaining was defined as
cytoplasmic and/or membrane immunoreactivity. The
level of reactivity in the immunostained tissues was eval-
uated independently by two pathologists who were
blinded to the subjects’ clinical information, and scored
into four groups according to the percentage and inten-
sity of cytoplasmic and membrane staining. Specimens
in which >30% of the cells were stained were scored as
strongly positive (+++), specimens in which 10–30% of
the cells were stained were scored as moderately positive
(++), and those in which <10% of the cells were stained
were scored as weakly positive (+). Specimens with no
staining were scored as negative (−) [18]. A high level of
EPOR expression was defined as staining of >10% of the
tumor cells, and a low level of EPOR expression was
defined as staining in <10% of the tumor cells.
Statistical analysis
Several clinicopathological factors were evaluated, in-
cluding gender, age (59 versus 60 years), T classification
(T1, T2 versus T3, T4), N classification (negative versus
positive), and TNM stage (stage I, II versus stage III, IV).
Fisher’s exact test was used to evaluate the correlation
between the clinicopathological variables and EPOR
expression. A p-value less than 0.05 was deemed to be sta-
tistically significant. The clinicopathological variables and
the expression of EPOR were taken into account for the
analysis of survival based on the Kaplan-Meier method;Table 1 Clinical profile and correlation between the
clinicopathological features and EPOR expression in oral









Male 239 133 106 0.128
Female 17 13 4
Age, years
<60 202 114 88 0.0758
≥60 54 32 22
T classification
T1, T2 94 73 21 <0.001*
T3, T4 162 73 89
N classification
Positive 103 46 57 <0.001*
Negative 153 100 53
TNM stage
I, II 66 60 6 <0.001*
III, IV 190 86 104
EPOR, erythropoietin receptor; *statistically significant (p< 0.05).statistical significance, defined as a p< 0.05, was assessed
using the log-rank test. To determine the effect of particu-
lar prognostic factors on survival, a multivariate analysis
was performed using Cox’s regression model.
Results
Immunohistochemical study of EPOR in OSCC tissues
The study included 239 men and 17 women with an
average age of 50.9 years (range, 26–87 years). Of the
256 patients, 39 were classified as T1, 55 as T2, 64 asFigure 2 Q-RT-PCR and Western blot analyses of EPOR
expression in oral squamous cell carcinoma (OSCC). (A) The
mRNA expression level of EPOR was determined by Q-RT-PCR in
12-paired OSCC patients (from early tumor stage to late tumor
stage). Results were normalized against the expression level of
GAPDH mRNA in each sample. (B) The Western blot analysis showed
high EPOR expression in the tumor tissue compared with that in the
adjacent non-tumor tissue in 8-paired tissue samples (from early
tumor stage to late tumor stage). β-Actin was used as an internal
control. EPOR, erythropoietin receptor; N, adjacent non-tumor tissue;
T, tumor tissue.
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patients (59.8%), N1 in 38 (14.8%), N2b in 48 (18.7%),
N2c in 13 (5.1%), and N3 in 4 (1.6%) patients. The can-
cer stage was classified as I in 32 patients (12.5%), II in
34 (13.3%), III in 63 (24.6%), and as stage IV in 127
(49.6%) patients (Table 1). The mean follow-up period
was 67 months (range, 2–171 months).
EPOR immunoreactivity was observed in the neoplas-
tic epithelial cells of the OSCC (Figure 1A and B). Late-
stage OSCC was characterized by diffuse and strong
EPOR immunoreactivity in the neoplastic epithelial cells







Figure 3 The 5-year (a) overall and (b) disease-specific survival rates w
low level of EPOR immunostaining in the tumor had a significantly better s
immunostaining.expression in 146 patients and high expression in 110.
Table 1 shows EPOR expression in the cancer cells and
the correlation with clinicopathological variables. High
expression of EPOR was significantly correlated with the
advanced T classifications (p< 0.001), positive N classifi-
cation (p= 0.001), and an advanced TNM stage
(p< 0.001).
RT-PCR and western blot analyses
EPOR expression was measured in 12 paired samples of
tumor tissue and adjacent non-tumor oral tissue (from
early to late stage) using Q-RT-PCR. EPOR mRNA wasPOR expression  
OR expression  
 0.0011
R expression  
R expression  
ere assessed using the Kaplan-Meier analysis. The patients with a
urvival rate compared to those with a high level of EPOR
Table 3 Correlation between the 5-year disease-specific
survival rate and clinicopathological features in oral







Male 239 64.8 0.174
Female 17 81.9
EPOR
Low expression 146 73.5 0.0017*
High expression 110 55.9
Age, years
<60 202 67.9 0.142
≥60 54 58.6
T classification
T1, T2 94 81.9 <0.001*
T3, T4 162 56.6
N classification
Negative 153 79.4 <0.001*
Positive 103 45.8
TNM stage
I, II 66 90.9 <0.001*
III, IV 190 57.2
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higher level of EPOR in the tumor tissue than in the ad-
jacent non-tumor oral tissue after normalization using
GAPDH (Figure 2A). To confirm this finding, EPOR
protein expression was examined in 8 additional pairs of
tumor and adjacent non-tumor tissue using the Western
blotting technique. The results showed that EPOR
expression was higher in the tumor tissue than in the
adjacent non-tumor tissue in all four samples (Figure 2B),
indicating that EPOR expression is low in adjacent non-
tumor oral tissues and elevated in oral cancer tissues.
Relationship between the 5-year survival rate and EPOR
expression in OSCC
Patients with low levels of EPOR expression had a sig-
nificantly higher 5-year overall survival rate than
patients with high levels of EPOR (p= 0.0011; Figure 3A).
Similarly, the 5-year disease-specific survival rate in
patients with low EPOR expression was significantly
higher than that in patients with high EPOR expression
(p= 0.0017; Figure 3B). Furthermore, patients with
advanced T classification, positive N classification, or
advanced TNM stage had significantly lower 5-year
overall and disease-specific survival rates compared to
patients with early T classification, negative N classifica-
tion, or early TNM stage (all p< 0.001; Tables 2 and 3).Table 2 Correlation between the 5-year overall survival








Male 239 60.8 0.1
Female 17 81.9
EPOR
Low expression 146 69.6 0.0011*
High expression 110 51.5
Age, years
<60 202 64.5 0.0685
≥60 54 51.9
T classification
T1, T2 94 79.8 <0.001*
T3, T4 162 50.7
N classification
Negative 153 75 <0.001*
Positive 103 41.2
TNM stage
I, II 66 89.4 <0.001*
III, IV 190 52.2
EPOR, erythropoietin receptor; *statistically significant (p< 0.05).
EPOR: erythropoietin receptor; *statistically significant (p< 0.05).However, the multivariate analysis using Cox’s regression
model revealed that only the T and N classifications
were independent prognostic factors for the 5-year over-
all survival rate (p= 0.015) and 5-year disease-specific
survival rate (p= 0.0025; Tables 4 and 5).
Discussion
EPOR is highly expressed in the tumor cells of head and
neck cancer, particularly in the hypoxic and infiltrating
areas. EPOR rather than EPO may be upregulated by
hypoxia in the tumor bed, and the high expression of
EPOR in the tumor tissue may promote neck lymph
node metastasis [19]. High EPOR expression in tumor
tissue was found to be significantly correlated with high
microvascular density in tongue cancer in an immuno-
histochemical study [18]. This finding suggests that theTable 4 Risk factors affecting 5-year overall survival rate







T3, T4 vs. T1, T2 2.219 1.171–4.206 0.015
N classification
Positive vs. Negative 2.651 1.679–4.187 <0.001
Table 5 Risk Factors affecting 5-year disease-specific
survival rate determined by Cox’s regression analysis




T3, T4 vs. T1, T2 2.152 1.103–4.202 0.025
N classification
Positive vs. Negative 2.651 1.766–4.763 <0.001
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angiogenesis and promote tumor survival and growth.
EPOR in normal hematopoietic tissues is responsible
for normal erythropoiesis. Abnormal EPOR function is
associated with proliferative disorders of bone marrow
such as primary erythrocytosis [15]. EPOR overexpres-
sion in tumor tissue is associated with a poor prognosis
in a variety of malignancies, including breast cancer [20-
23], melanoma [24], renal cell carcinoma [25], gastric
cancer [26], pediatric tumors [27], and uterine and ovar-
ian carcinoma [28]. However, only a few studies with
limited cases have investigated the prognostic role of
EPORs in OSCC. Recent studies have reported that EPO
and EPORs are adverse prognostic factors for overall
survival in patients with SCC of the tongue. Roh et al.
[29] evaluated the prognostic value of hypoxia markers
in 43 cases of T2-staged oral tongue cancer. They inves-
tigated the association between the 5-year survival rate
and hypoxia biomarkers, such as HIF-1α, IF-2α, CA-9,
GLUT-1, and EPOR, and found that EPOR was an inde-
pendent biomarker in these patients, with a high pro-
pensity for regional metastasis Li et al. [18] reported that
EPORs influenced the prognosis of carcinogenesis,
angiogenesis, and the malignant progression in SCC of
the tongue. Moreover, they found that EPORs were an
independent prognostic marker. The results of our study
are consistent with those of Li et al. [18] and suggest
that EPOR is a significant prognostic indicator in patient
with oral cancer. Thus, EPOR may play a role in tumor
proliferation, apoptosis, and angiogenesis [30].
The TNM staging system is used to evaluate and pre-
dict the prognosis of patients with head and neck SCC
(HNSCC). Clinicians develop therapeutic strategies
according to the TNM stage of patients. Biomarkers that
could reliably predict tumor behavior would be useful in
the clinical setting. The clinical value of biomarkers
related to angiogenesis and hypoxia in patients with
HNSCC had been established in recent years [31-36].
These biomarkers were significantly correlated with
tumor invasiveness and prognosis. The present study
investigated EPOR expression in a large sample of
patients with OSCC using immunohistochemical ana-
lysis. We found that a high EPOR expression was signifi-
cantly correlated with advanced T classification, positiveN classification, and advanced TNM stage. It represents
the rapid proliferation of tumor cells may outpace the
blood and nutrition supply. This probably leads to tumor
necrosis and hypoxia in the microenvironment of tumor
and may result into the higher level of EPOR. Further-
more, EPOR levels had a significant impact in the 5-year
overall and 5-year disease-specific survival rates. We
found that EPOR was overexpressed at both the mRNA
and protein levels (data of Western blot assay) in OSCC
tumors. Our findings are consistent with several reports
showing that patients with oral cancer who had a high
levels of EPOR expression had a poor 5-year overall sur-
vival rate [18,29]. To avoid the impact of other adjuvant
treatment in the result of survival, the patients with high
expression of EPOR still showed the poorer 5-year dis-
ease-specific survival significantly among patients under-
went surgery only (p= 0.0079).
Conclusions
High EPOR expression in patients with OSCC was asso-
ciated with tumor progression in the present compre-
hensive study. These results suggest that EPOR
expression is an important prognostic factor for OSCC.
Thus, EPOR expression may serve as a treatment target
for OSCC in the future.
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